GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corp (OTCPK:VASO) » Definitions » 5-Year ROIIC %

Vaso (VASO) 5-Year ROIIC % : -317.44% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Vaso 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Vaso's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -317.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Vaso's 5-Year ROIIC % or its related term are showing as below:

VASO's 5-Year ROIIC % is ranked worse than
97.52% of 565 companies
in the Healthcare Providers & Services industry
Industry Median: 1.51 vs VASO: -317.44

Vaso 5-Year ROIIC % Historical Data

The historical data trend for Vaso's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaso 5-Year ROIIC % Chart

Vaso Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.51 -82.36 -205.70 -8,764.64 -317.44

Vaso Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -317.44 - - -

Competitive Comparison of Vaso's 5-Year ROIIC %

For the Health Information Services subindustry, Vaso's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaso's 5-Year ROIIC % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vaso's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Vaso's 5-Year ROIIC % falls into.



Vaso 5-Year ROIIC % Calculation

Vaso's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( 4.109422 (Dec. 2023) - -3.375806 (Dec. 2018) )/( 52.773 (Dec. 2023) - 55.131 (Dec. 2018) )
=7.485228/-2.358
=-317.44%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Vaso  (OTCPK:VASO) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Vaso 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Vaso's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaso Business Description

Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corp is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
Jun Ma director C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Leon Dembo director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Edgar Rios director 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher officer: Chief Financial Officer C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz director 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton officer: Vice Pres Finance & Controller 152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle director C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman director 3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi director C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill officer: Senior Vice President 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey director 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh officer: Chief Financial Officer C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone director
Derek Enlander director 88C UNION AVENUE, CENTER MORICHES NY 11934